SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 15. SUBSEQUENT EVENTS In December 2025, the Company entered into a services agreement with IRTH Communication, LLC for investor relations, financial communications and strategic consulting. Per the agreement, the Company was to issue $125,000 worth of Common Stock calculated by the average closing price of the Company’s common stock on its principal exchange for the ten (10) trading days immediately prior to execution of the Agreement. In July 2026, the Company issued 92,524 shares of Common Stock at $1.35 per the consulting agreement. In July 2026, holders of the Company’s Series B Convertible Preferred Stock elected to convert 150 shares of such Series B Convertible Preferred Stock into an aggregate of 49,999 shares of Common Stock in accordance with the Convertible Preferred Stock described in Note 12. In July and August 2026, investors in the June direct offering, described in Note 12, exercised an additional 1,180,000 pre-funded warrants convertible into an equivalent number of Common Stock. In July 2026, the Company announced a collaboration with Pictor®, Inc. (“Pictor”), a targeted proteomic platform company, to support development and commercialization of bioAffinity Technologies’ next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and COPD. Pictor. is led by CEO and Managing Director Jamie Platt, PhD, a recognized diagnostics executive who joined bioAffinity Technologies’ Board of Directors in 2023. In July 2026, the Company received notice from Nasdaq noting the Company’s bid price for its Common Stock closed at less than $1 per share over the previous 30 consecutive business days as of July 29, 2026, and has not regained compliance according to Listing Rule 5550(a)(2). As of August 6, 2026 the Company requested a hearing appeal on the determination. Such request will stay any further action by Nasdaq and will allow the Company’s ordinary shares to continue to trade on Nasdaq under the symbol “BIAF” at least pending the issuance of the Panel’s decision and the expiration of any extension the Panel may grant to the Company following the appeal.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2026

Note 15. SUBSEQUENT EVENTS

In December 2025, the Company entered into a services agreement with IRTH Communication, LLC for investor relations, financial communications and strategic consulting. Per the agreement, the Company was to issue $125,000 worth of Common Stock calculated by the average closing price of the Company’s common stock on its principal exchange for the ten (10) trading days immediately prior to execution of the Agreement. In July 2026, the Company issued 92,524 shares of Common Stock at $1.35 per the consulting agreement.

In July 2026, holders of the Company’s Series B Convertible Preferred Stock elected to convert 150 shares of such Series B Convertible Preferred Stock into an aggregate of 49,999 shares of Common Stock in accordance with the Convertible Preferred Stock described in Note 12.

In July and August 2026, investors in the June direct offering, described in Note 12, exercised an additional 1,180,000 pre-funded warrants convertible into an equivalent number of Common Stock.

In July 2026, the Company announced a collaboration with Pictor®, Inc. (“Pictor”), a targeted proteomic platform company, to support development and commercialization of bioAffinity Technologies’ next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and COPD. Pictor. is led by CEO and Managing Director Jamie Platt, PhD, a recognized diagnostics executive who joined bioAffinity Technologies’ Board of Directors in 2023.

In July 2026, the Company received notice from Nasdaq noting the Company’s bid price for its Common Stock closed at less than $1 per share over the previous 30 consecutive business days as of July 29, 2026, and has not regained compliance according to Listing Rule 5550(a)(2). As of August 6, 2026 the Company requested a hearing appeal on the determination. Such request will stay any further action by Nasdaq and will allow the Company’s ordinary shares to continue to trade on Nasdaq under the symbol “BIAF” at least pending the issuance of the Panel’s decision and the expiration of any extension the Panel may grant to the Company following the appeal.